Efficacy and Safety of Endovascular Therapy for 34 cases of Progressive Ischemic Stroke in Posterior Circulation with Large Artery Stenosis/Occlusion

doi:10.21203/rs.3.rs-1877700/v1

Download PDF

Article

Efficacy and Safety of Endovascular Therapy for 34 cases of Progressive Ischemic Stroke in Posterior Circulation with Large Artery Stenosis/Occlusion

https://doi.org/10.21203/rs.3.rs-1877700/v1

This work is licensed under a CC BY 4.0 License

Version 1

posted

You are reading this latest preprint version

It is unclear whether endovascular therapy (ET) can improve the prognosis of posterior circulation progressive ischemic stroke (PIS) due to large vessel stenosis/occlusion. The purpose of this study was to evaluate the efficacy and safety of ET for patients with PIS in posterior circulation who were selected based on ischemic penumbra detected on brain imaging. According to inclusion and exclusion criteria, patients with posterior circulation PIS hospitalized in the Second Affiliated Hospital of Nanchang University from May 2020 to December 2021 were retrospectively included and divided into ET + standard medical therapy (SMT) and SMT according to actual treatment conditions. Our research shows that ET is more effective than conservative therapy of Progressive Ischemic Stroke in Posterior Circulation with Large Artery Stenosis/Occlusion. In those patients with high NIHSS scores, ET had better neurological function recovery than conservative treatment. Delayed recanalization still has better therapeutic effect.

The incidence of posterior circulation progressive ischemic stroke (PIS) can reach 34%¹. When the lesions involve the reticular activation system, circulation center and respiratory system, once the disease progresses, it is very dangerous and endangers the life safety of patients. PIS in posterior circulation has been mainly treated with drugs, despite active treatment, there is still a high rate of disability and mortality. With the improvement of thrombectomy devices, the time window of endovascular therapy (ET) has been extended from 6 hours to 24 hours in just 5 years for anterior circulation^2-3. Up to now, DIRECT-MT study has shown that it is possible to skip intravenous thrombolysis (IVT) and direct mechanical thrombectomy⁴. However, there are few large randomized clinical trials studies on posterior circulation treated with ET. The BEST⁵study led by Chinese scholars published in 2019 provided the highest level of evidence for vertebro-basilar artery ET, however, whether ET can improve the prognosis of PIS patients in posterior circulation is unclear. Patients with PIS of posterior circulation can only present with dizziness and unstable walking, insidious onset and easy to be ignored. When these patients come to the hospital with worsening condition, they have missed the time window of IVT and ET within 24 hours^2–3. For patients with PIS of posterior circulation caused by stenosis or occlusion of large vessels, the response to drug therapy is poor. What is the effect of ET within the time window? And what is the effect of out-of-time window? These are all questions we need to explore. Currently, there have been studies of anterior circulation comparing the effects of ET in early (within 6 hours) and late (6-72 hours), and the results prove that patients can still benefit from late revascularization⁶, while there are few reports on the effect of ET beyond the time window of the posterior circulation. The success of ET in the anterior circulation brings more treatment options for patients with PIS of posterior circulation. In this study, PIS of posterior circulation patients were selected as the research objects, and a single-center observational study was conducted to evaluate the effect of ET for PIS of posterior circulation, so as to provide evidence for the treatment direction and improve prognosis of PIS in posterior circulation.

Patients

Patients with posterior circulation PIS who were hospitalized in the Department of Neurology, The Second Affiliated Hospital of Nanchang University from May 2020 to December 2021 were consecutively enrolled, aggravating patients were treated with intravascular interventional + standard medical therapy (SMT) as the ET+SMT group, treated with pure standard drug treatment as the SMT group. All methods were approved and were performed in accordance with guidelines and regulations set by the Second Affiliated Hospital of Nanchang University Medical Research Ethics Committee, and have been performed in accordance with the Declaration of Helsinki. Informed consent was obtained from all participants and/or their legal guardians. The PIS of posterior circulation was associated with the following conditions: (1) MRI confirmed posterior circulation cerebral infarction; Meet PIS of posterior circulation definition; (2) Onset-to-ET time was beyond 6 hours; (3) MRA/CTA/DSA suggested intracranial/extracranial large artery stenosis or occlusion; (4) Patients with informed consent can cooperate to complete the study indicators; (5) modified Rankin Scale (mRS) score was 0-2 before stroke. And Exclusion criteria include: (1) Patients with cerebral hemorrhage or hemorrhage transformation after infarction; (2) Exceeded 7 days when aggravation; (3) Patients received IVT; (4) Patients who did not cooperate with follow-up; (5) Patients with malignant tumors, infectious diseases, autoimmune diseases or other serious diseases; (6) Patients with anterior circulation cerebral infarction.

Definition of PIS in posterior circulation

The widely used definition of PIS is the aggravation of the patient's condition within 24 hours of onset, and the increase of ≥4 points in the National Institutes of Health Stroke Scale (NIHSS) score is defined as PIS⁷. In our view, PIS of posterior circulation defined as within 7 days of onset, after conventional treatment such as anti-platelet, anticoagulant, lipid regulation, improve circulation, nerve protection, et al., neurological impairment still made progress, ∆NIHSS score increased ≥4 points, and lesions only involved in posterior circulation. When ∆NIHSS score <4 points, but with new lesions on imaging could still be functionally meaningful⁸.

Study design

Treatment options

The ET+SMT group received Solitaire thrombectomy, angioplasty and standard drug therapy. After mechanical thrombectomy, significant vascular stenosis still existed, such as stenosis > 70% or stenosis affects distal flow [modified Thrombolysis In Cerebral Infarction scale(mTICI)<2b] or lead to repeated reocclusion, angioplasty (balloon dilation and/or stent placement)^9-10 can be considered. The SMT group received aspirin 100 mg/d + clopidogrel 75 mg/d, continuous treatment for 3 months, or tirofiban 0.1 μg/kg/min, continuous treatment for 3-5 days, sequential aspirin+ clopidogrel, or argatroban/argatroban + clopidogrel for 7 days, sequential aspirin+ clopidogrel. When the cause is considered as cardiogenic embolism, only single antiplatelet therapy can be used after surgery, according to the condition switched to anticoagulant therapy at the later stage. It is recommended to re-examine CT 24 hours after intervention to exclude hemorrhage transformation and then give bigeminy antiplatelet therapywhenconsidering the formation of atherosclerosis. During the treatment of both groups, statins were given to strengthen lipid-lowering, blood glucose and blood pressure would be control, dehydration and reduces intracranial pressure could be performed if necessary. If the condition is stable or improved, head CT examination can be performed within 36 hours after interventional treatment to evaluate intracranial hemorrhage. CT or MRI were used to assess posterior circulation Acute Stroke Prognosis Early CT score (pc-ASPECTS) and intracranial hemorrhage.

Data gathering

Basic information of the two groups was collected, including age, sex, medical history, history of alcohol and tobacco, etiology of cerebral infarction, responsible vessels, NIHSS score at onset, NIHSS score at exacerbation, pc-ASPECTS, complications, rate of vascular recanalization, and clinical outcome, NIHSS score and mRS score at 90 days. The main clinical outcome of the study was the proportion of patients with mRS 0-3 at 90 days; secondary clinical outcomes included the proportion of patients with mRS 0-2 at 90 days, NIHSS score at 90 days, and the distribution of mRS score. Secondary imaging outcomes included the rate of vascular recanalization (mTICI≥2b) in two groups, brain CTA/MRA showing severe stenosis/occlusion at admission was regarded as mTICI<2b. The primary endpoint for safety outcome was mortality at 90 days. Secondary endpoints were rate of symptomatic intracranial hemorrhage (sICH), and other serious adverse events included stroke-associated pneumonia (SAP) and heart failure. All images were read separately by two experienced neurologists, differences between the two were resolved by consensus. Clinical data and images informed consent was obtained from all participants and/or their legal guardians.

Statistical Analysis

Continuous variables were analyzed with the Student t test or Mann–Whitney U test according to their normality of distribution. Categorical variables were analyzed with χ² or Fisher exact tests. The primary and secondary outcomes, safety events and adverse events were analyzed by linear regression analysis or Logistic regression analysis, and the survival analysis was analyzed by K-M curve analysis. We selected these confounders on the basis of their associations with the outcomes of interest or a change in effect estimate of more than 10%. P < 0.05 in data comparison indicated that the difference was statistically significant. Statistical analysis were performed using R version 3.4.3(www.R-project.org)and Empower States（www.Empowerstats.com).

Of the 36 patients were included. According to literature review during the collection process, 1 case in the ET + SMT did not meet the inclusion criteria, and 1 case in the ET + SMT had a history of lung cancer during the follow-up, which was excluded according to the exclusion criteria. In the final, 21 cases into ET + SMT, and no case was lost to follow-up, 13 cases in the SMT, and 1 case was lost to follow-up(Fig. 1).

Comparison of clinical data between the two groups

Mean age was 57.52 ± 14.66 years in ET + SMT and 67.31 ± 6.56 years in SMT. There were 18(85.71%) in ET + SMT and 7(53.85%) in SMT for stroke caused by basilar artery stenosis or occlusion, 14(66.67%) vs. 8(61.54%) caused by vertebral artery, 8(38.10%) vs. 5(38.46%) caused by posterior cerebral artery. Stroke could be caused by one or more responsible arteries at the same time in both groups. Comparison of baseline population characteristics showed that there were no significant differences in age, sex, past history, tobacco and alcohol history, NIHSS score at onset and exacerbation, causes of stroke, pc-ASPECTS score, and different responsible vessels between the two groups (P > 0.05), preoperative baseline characteristics of the two groups were consistent (Table 1).

Table 1

Characteristics of ET + SMT group and SMT group
	ET + SMT(n = 21)	SMT(n = 13)	p value
Age(years)	57.52 ± 14.66	67.31 ± 6.56	0.067
Sex			0.362
Man	16 (76.19%)	8 (61.54%)
Women	5 (23.81%)	5 (38.46%)
Medical history
Hypertension	19(90.48%)	13(100.00%)	0.251
Diabetes	8(38.10%)	6 (46.15%)	0.643
Coronary heart disease	3 (14.29%)	3(23.08%)	0.513
Stroke	6 (28.57%)	3 (23.08%)	0.724
Atrial fibrillation	2 (9.52%)	3 (23.08%)	0.278
Smoking	6 (28.57%)	6 (46.15%)	0.297
Drinking	6 (28.57%)	1 (7.69%)	0.143
NIHSS score at onset	2(1–5)	2(0–10)	0.182
NIHSS score at aggravation	11(9–15)	14(8–27)	0.128
Cause of stroke			0.093
Atherosclerotic	19 (90.48%)	9 (69.23%)
Cardiac embolism	1 (4.76%)	4 (30.77%)
Other or unknown	1 (4.76%)	0
pcASPECTS	6.71 ± 1.59	7.46 ± 1.61	0.194
Offending vessel
Basilar artery	18 (85.71%)	7 (53.85%)	0.057
Vertebral artery	14 (66.67%)	8 (61.54%)	0.761
Posterior cerebral artery	8 (38.10%)	5 (38.46%)	0.983
Data continuous variable is ̅x ± S/IQR(Q1-Q3),classification variable is n(%).NIHSS = National Institutes of Health Stroke Scale. pcASPECTS = posterior circulation Acute Stroke Prognosis Early CT score.Smoking history refers to smoking ≥ 1 cigarette/day, duration ≥ 1 year, or cessation time ≤ 6 months; Drinking history refers to drinking ≥ 0.1kg/day and duration ≥ 1 year.

Primary and secondary outcomes were compared between the two groups at 90 days

Multivariate logistic regression analyses of primary outcome showed that 17(80.95%) in ET + SMT and 6(50%) in SMT of mRS 0–3 at 90 days, compared with crude regression analyses, the associations did not change markedly after adjusting for age, sex in the multivariable regression analyses(P > 0.05, adjusted OR = 5.35, 95%CI 0.87–33.01), secondary outcome of mRS 0–2 were 16 (76.19%) in ET + SMT and 5 (41.67%) in SMT, after adjustment, there was difference between the two groups (P < 0.05, adjusted OR = 6.98, 95%CI 1.10-44.07)

(Table 2, Fig. 2). For mTICI ≥ 2b, the results showed that there were all recanalization in ET + SMT, no recanalization in SMT (100% vs. 0, P < 0.001). After adjusting for age, sex, mRS scores in ET + SMT was 2.15 points lower than that in SMT (β=−2.15, 95%CI − 3.99-−0.31), however NIHSS score was lower by 0.70 points (β=−0.70, 95%CI − 2.97–1.56),

Table 2

Main and secondary results of ET + SMT group and SMT group
	ET + SMT (n = 21)	SMT (n = 12)	Unadjusted OR/β(95%CI)	Adjusted* OR/β(95%CI)
Primary outcome
mRS 0–3	17(80.95%)	6(50.00%)	4.25 (0.88–20.44)	5.35 (0.87–33.01)
Secondary outcome
mRS 0–2	16(76.19%)	5(41.67%)	4.48 (0.97–20.59)	6.98 (1.10-44.07)
mRS score	1(0–2)	4.50 (1.75-6.00)	−1.86(− 3.45- −0.27)	−2.15 (− 3.99-−0.31)
NIHSS score at 90 days	1(0–2)	2.50 (0.50–3.75)	−0.61 (− 2.72–1.50)	−0.70 (− 2.97–1.56)
mTICI ≥ 2b	21(100%)	0	NA	NA
Data continuous variable is ̅x ± S/IQR(Q1-Q3),the classification variable is n(%),mRS = modified Rankin Scale,NIHSS = National Institutes of Health Stroke Scale, mTICI = modified Thrombolysis In Cerebral Infarction scale,OR = odds ratio,β = effect value of regression analysis, NA = not applicable.*Adjusted for age,sex.

the scores were small and had no clinical significance. In addition, follow-up results in both groups showed that patients with lower deteriorative NIHSS scores tended to have lower or no significant increase in NIHSS scores and mRS scores at 90 days(NIHSS < 15, median baseline mRS 1, IQR 0.5-2, in ET + SMT vs 1.5, 0.25–2.75, in SMT; median baseline NIHSS 1, IQR 0–2, in ET + SMT vs 2, 0–3, in SMT). However, among patients with severe neurological deficits at the time of exacerbation (NIHSS ≥ 15), mRS scores in ET + SMT were 3.33 points lower than those in SMT (β=−3.33, 95%CI − 5.69- −0.98)(Table 3).

Table 3

Multivariate Analysis of Different degrees of stroke
	Deteriorative NIHSS ≥ 15		OR/β(95%CI)	Deteriorative NIHSS < 15		OR/β(95%CI)
	ET + SMT (n = 6)	SMT (n = 6)		ET + SMT (n = 15)	SMT (n = 6)
mRS 0–2	4 (66.67%)	1 (16.67%)	10.00(0.65–154.40)	12 (80.00%)	4 (66.67%)	2.00 (0.24–16.61)
mRS 0–3	4 (66.67%)	1 (16.67%)	10.00(0.65–154.40)	13 (86.67%)	5 (83.33%)	1.30 (0.10-17.73)
mRS score	1 (0.25–3.25)	NA	−3.33(− 5.69- −0.98)	1 (0.5-2)	1.5(0.25–2.75)	−0.27 (− 2.20–1.66)
NIHSS score at 90 days	1 (0–2)	NA	−1.80 (− 8.99–5.39)	1(0–2)	2 (0–3)	−0.46 (− 2.54–1.62)
Data continuous variable is‾x ± S or IQR(Q1-Q3),the classification variable is n(%),mRS = modified Rankin Scale,NIHSS = National Institutes of Health Stroke Scale,OR = odds ratio,β = effect value of regression analysis,NA = not applicable.

The safety analysis of the two groups was compared

Multivariate logistic regression safety analysis showed that there were no significant differences in sICH, SAP and heart failure between the two groups (P > 0.05). Among the 21 patients in ET + SMT, 3 (14.29%) died (2 due to higher NIHSS score in exacerbation and 1 due to reperfusion injury and hemorrhage transformation), while in SMT, 6 (50.00%) died (4 due to higher NIHSS score in exacerbation and 2 due to serious complications). The ET + SMT had a lower mortality than the SMT (P = 0.035, OR = 0.17, 95%CI 0.03–0.88). As none of the enrolled patients underwent IVT, the incidence of intracranial hemorrhage was low, mainly due to reperfusion injury and hemorrhage transformation after thrombectomy. There were 2 asymptomatic hemorrhage and 1 sICH in the ET + SMT(Table 4). As for the prognosis of patients during follow-up, K-M survival curve analysis showed that: with the extension of follow-up time, the survival rate of the ET + SMT was higher than that of the SMT, and the risk of long-term recurrence of cerebral infarction decreased (Fig. 3).

Table 4

Safety analysis results of ET + SMT group and SMT group
	ET + SMT (n = 21)	SMT (n = 13)	OR(95% CI)	p value
Security events
Mortality at 90 days	3 (14.29%)	6(50.00%,n = 12)	0.17 (0.03–0.88)	0.035
sICH	1 (4.76%)	0	NA	0.361
Serious adverse events
SAP	9 (42.86%)	4(30.77%)	1.69 (0.39–7.27)	0.483
Heart failure	1 (4.76%)	2(15.38%)	0.28 (0.02–3.39)	0.314
classification variable is n(%),OR = odds ratio,NA = not applicable,sICH = symptomatic intracranial haemorrhage,SAP = stroke-associated pneumonia.

Effect of delayed recanalization

Among the 21 patients in ET + SMT, the shortest time of onset-to-deterioration was 4 hours, the longest was 7 days, median time of onset-to-deterioration was 1 day. The shortest time of onset-to-ET was 6 hours, it was a 52-year-old male with lesions involving basilar artery, vertebral artery and posterior cerebral artery, his NIHSS score was 3 at the onset, 13 at the aggravation, NIHSS score was 7 and mRS score was 3 at 90 days after ET. The longest time of onset-to-ET was 16 days, it was a 57-year-old male who had NIHSS score of 0 at onset and 4 at aggravation, and a 53-year-old female who had NIHSS score of 6 at onset and 10 at aggravation. The lesions of both patients involved basilar artery. Their 90-day NIHSS score and mRS score were 0, 0 and 2, 1, respectively. Median time of onset-to-ET was 3 days. Aggravation-to-ET time was more than 24 hours in 7 patients, and 1 patient died in postoperative follow-up at 90 days, mRS score of the remaining patients was 0–2, they were basically able to take care of themselves (Table 5), an illustrative case is shown as Fig. 4.

Table 5

Cases of interventional treatment in ET + SMT group
case	gender/age(years)	Offending vessel	Onset NIHSS score	Deteriorative NIHSS score	onset-to- Aggravation time	onset-to-ET time	NIHSSscore at 90 days	mRS score
1	M/52	VA、BA、PCA	3	13	4h	6h	7	3
2	M/72	VA	10	23	6h	8h	die	6
3	M/51	VA、BA	18	30	5h	11h	8	4
4	M/29	BA	4	8	1d	1d	0	0
5	M/70	VA、BA、PCA	7	11	1d	1d	1	1
6	M/67	VA、BA、PCA	2	15	1d	1d	0	1
7	M/62	BA	0	20	1d	1d	1	0
8	M/86	VA、BA	1	10	1d	2d	1	2
9	M/58	VA、BA	3	11	1d	3d	3	2
10	F/65	VA、BA、PCA	3	9	2d	3d	3	2
11	F/30	BA	6	15	3d	3d	0	0
12	F/57	VA、BA	1	18	3d	3d	2	1
13	M/51	VA、BA、PCA	0	11	3d	3d	die	6
14	M/45	VA、PCA	2	9	1d	4d	0	0
15	F/68	BA	2	8	7d	7d	0	1
16	M/68	VA、BA	2	6	1d	7d	1	1
17	M/64	BA、PCA	1	10	7d	7d	2	1
18	M/32	VA、BA	5	13	5d	10d	die	6
19	M/71	VA、PCA	2	6	7d	15d	0	0
20	F/53	BA	6	10	4d	16d	2	1
21	M/57	BA	0	4	5d	16d	0	0
M = male, F = female, VA = vertebral artery, BA = basilar artery, PCA = posterior cerebral artery, mRS= modified Rankin Scale,NIHSS = National Institutes of Health Stroke Scale.

There was no significant difference in baseline data between ET + SMT group and SMT group, which made it possible to compare the treatment effects between the two groups. In the ET + SMT group, mRS 0–2 and mRS score in multivariate Logistic regression analysis and linear regression analysis were better than those in the SMT group. ET did significantly improve the living quality of patients with PIS of posterior circulation, and have improved neurologic impairment and survival of patients with a higher deteriorative NIHSS score (NIHSS ≥ 15). Traditional antiplatelet, anticoagulant, reduce blood lipids, improve circulation, difficult to dissolve the mass of stearic plaque or large thrombi, ET can increase the rate of vascular recanalization in patients with low-perfusion watershed infarction caused by large artery stenosis/occlusion, and did not increase the risk of symptomatic intracranial hemorrhage. The risk of SAP and heart failure was similar in both groups. The brain tissue of ischemic penumbra was not completely necrotic, recanalization and blood flow reperfusion were achieved in the early stage of ET. The symptoms of dizziness, paralysis and consciousness disturbance were improved, and the patient could take the initiative to recover, reduce time of ventilator use, bed time and complications, and improve the survival rate. The follow-up results of the two groups showed that patients with low NIHSS score at the time of progression tended to have lower or no significant increase NIHSS score and mRS score 90 days later, with a better prognosis. Conservative treatment could be selected for these patients, but longer follow-up time is needed to verify the long-term prognosis. In this study, 9 patients died, which may be related to the change of the patient's consciousness level affecting swallowing function, vomiting and aspiration, and long-term bed rest, combined with SAP and heart failure during hospitalization. The mortality of patients in the ET + SMT group was lower than that in SMT group, which was statistically different from the previous results of BEST⁵. This may be related to the small sample size, which needs to be verified by further large-scale studies. In addition, the cases collected during the same period were more willing to choose interventional, which may also result in fewer cases in SMT group than in ET + SMT group. Previous studies on intravascular therapy for ischemic stroke did not include patients with posterior circulation vascular diseases in order to promote intravascular therapy in pursuit of better therapeutic effect. Based on the study of anterior circulation endovascular therapy, the BEST⁵ study provided the highest level of evidence for thrombectomy for vertebro-basilar artery occlusion, suggesting that ET for stroke patients with acute vertebro-basilar artery occlusion may be safe and feasible. The guidelines suggest that mechanical thrombectomy should be considered after imaging evaluation in patients with acute basilar artery occlusion within 6–24 hours of onset. For patients with large vessel occlusion more than 24 hours after onset, the benefit of mechanical thrombectomy is not clear¹¹. In our study, as a result of some patients have mild onset symptoms, they didn't take it seriously, when they came to the hospital for aggravation, they had missed the best time for treatment, or a lesser degree of disability when aggravated, the patient and his family members did not agree to ET because of the risk of operation, when the pros and cons were weighed again or the disease got worse again, they decided to have ET treatment, the onset-to-ET time tend to be more than 24 hours, deterioration-to-ET time was also more than 24 hours, but we did it to save the ischemic penumbra rather than the core infarct. Animal experiments have shown that the volume of ischemic penumbra changes dynamically and can be identified by MRI¹². Due to the existence of collateral circulation, penumbra can persist for a period of time, therefore, delayed reperfusion of ischemic stroke can also improve neurological dysfunction by restoring blood flow to penumbra¹³, and clinical cases reported that patients can still benefit from ET 3 months or more after onset¹⁴. Infarct core was populated by microglial cells, endothelial cells, neural progenitor cells, and neural stem cells after recanalization, additionally, the penumbral region was abundant with neurons and astrocytes, cells in the area around the infarction might help remove debris and release pro-angiogenic, anti-inflammatory, and neuroprotective factors, neural stem cells can differentiate into new blood vessels, astrocytes and neurons, all of these will contribute to the recovery of brain tissue¹⁵. Another mechanism for protection of ischemic area is that permanent occlusion can stimulate the liver produce hepatocyte growth factor (HGF), serum release of fibroblast growth factor 21 (FGF21), FGF21 activated the FGFR1/PI3K/Caspase-3 signaling pathway, which attenuated neuronal apoptosis. A similar mechanism was observed for HGF. Bone marrow stem cells can be converted into new neurons, spleen macrophages can remove cellular debris, when recanalization, these beneficial cells and secreted factors reach the infarct area through blood flow and promote the repair of brain tissue^16–17. Our research shows that beyond the guidelines for 24 hours, ET can still improve the symptoms of patients with nerve function defect, has potential therapeutic value. MRI/CT perfusion was used in our study, Flair-DWI mismatches¹⁸ and ASL-DWI mismatches¹⁹ can reveal penumbra, which is conducive to ET. If ET is selected based on the presence of ischemic penumbra, it may be safe and feasible for PIS beyond the traditional 6 hours⁶. Since NIHSS scores are not sensitive to the posterior circulation, more studies are needed to better define PIS of posterior circulation. At this point, we can use MRI/CT perfusion mismatches to screen patients eligible for ET²⁰. With the improvement of the ability of more accurate and personalized measurement tools to identify the penumbra, it is valuable for suitable patients to ET even days or months after aggravation. Patients with delayed recanalization should be carefully selected according to their condition and be performed by an experienced clinician. For chronic stenosis or occlusion caused by atherosclerosis, ischemic area has certain compensatory ability, symptoms can be mild, there was no significant difference between angioplasty treatment and conservative treatment in these patients^21–22, the operation may be delayed after acute phase if the condition was stable and ET was required, but for associated with severe neurologic deficits, especially acute stroke caused by large artery embolism, lack of collateral compensatory, patients with onset nasty, serious, soon consciousness obstacle, reperfusion of the occluded artery should proceed as soon as possible. As a small sample study on the safety of ET for PIS of posterior circulation, linear regression analysis showed that among patients with severe neurological deficits at the time of deterioration (NIHSS ≥ 15), 90-day mRS scores in ET + SMT were 3.33 points lower than those in SMT, and delayed recanalization still benefited, which was consistent with the study on anterior circulation^6,23, but the indications for ET should be strictly controlled, age, underlying diseases, baseline NIHSS score, time window of ET, vascular lesions, related risk, willingness of patients and their families and cost of operation should be considered.

Some limitations of the present study must be addressed when interpreting the results. First of all, our study was a retrospective study, reviewing a small sample size database, which limited the ability to rectify differences between the two groups, in this study, only age, sex were adjusted. However, all data were measured by clinicians who were trained to record the data according to hospital standards. Secondly, we assumed that aspirin and clopidogrel were taken regularly for 90 days in two groups, although most of the follow-up of patients with long-term use of antiplatelet drugs or anticoagulant drugs, we don't know whether patients to stop taking one of antiplatelet drugs or replace other antiplatelet drugs, it is impossible to judge whether patients' medication compliance interferes with the study results.

In conclusion, our study provided evidence of a significant advantage in favourable neurological outcomes in patients treated with interventional therapy plus standard drug therapy compared with those treated with standard drug therapy alone. For PIS of posterior circulation due to large vessel stenosis/occlusion with severe neurological impairment, ET is preferred after aggressive conservative therapy, improves those patients outcome and survival. Delayed recanalization still has better therapeutic effect. It is hoped that this study will be validated and evaluated in a larger prospective, multicenter, randomized controlled trial.

Acknowledgements

The authors want to thank all the patients and participants involved in the study. Special thanks are due to Key R&D Plan of Jiangxi Provincial Department of Science and Technology - general project, for the fnancial support.

Author contributions

Dandan Li: Methodology, Formal analysis, Investigation, Data curation, Writing e original draft, Writing e review & editing, Visualization, Supervision. Yang Chen: Data curation, Methodology, Formal analysis, Supervision. Xin Luo: Data curation, Writing-original draft, Writing-review & editing. Zhijuan Cheng: Writing-original draft, Writing guidance. Keqi Lei: Data collection, Investigation, Visualization. Weiping Chen: Data curation, Data interpretation, Writing-review & editing. Min Yin: Data curation, Data interpretation. Fang Li, Kai Wang: Data collection, Writing-original draft. Jianglong Tu: Methodology, Writing guidance, Writing-review & editing, Supervision.

Competing interests

The authors declare no competing interests.

Availability of data and materials

Correspondence and requests for materials should be addressed to Jianglong Tu.

Sumer M, Ozdemir I, Erturk O. Progression in acute ischemic stroke: frequency, risk factors and prognosis. J Clin Neurosci 10(2),177–180(2003).
Nogueira RG, Jadhav AP, Haussen DC, et al. Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct. N Engl J Med 378(1),11–21(2018).
Albers GW, Marks MP, Kemp S, et al. Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging. N Engl J Med 378(8),708–718(2018).
Yang P, Zhang Y, Zhang L, et al. Endovascular Thrombectomy with or without Intravenous Alteplase in Acute Stroke. N Engl J Med 382(21),1981–1993(2020).
Liu X, Dai Q, Ye R, et al. Endovascular treatment versus standard medical treatment for vertebrobasilar artery occlusion (BEST): an open-label, randomised controlled trial. Lancet Neurol 19(2),115–122(2020).
Chen WH, Yi TY, Wu YM, Zhang MF, Lin DL, Lin XH. Safety of Endovascular Therapy in Progressive Ischemic Stroke and Anterior Circulation Large Artery Occlusion. World Neurosurg 122,e383-e389(2019).
Seners P, Baron JC. Revisiting 'progressive stroke': incidence, predictors, pathophysiology, and management of unexplained early neurological deterioration following acute ischemic stroke. Journal of neurology 265(1),216–225(2018).
Thanvi B, Treadwell S, Robinson T. Early neurological deterioration in acute ischaemic stroke: predictors, mechanisms and management. Postgraduate medical journal 84(994),412–417(2008).
Jia B, Feng L, Liebeskind DS,et al. Mechanical thrombectomy and rescue therapy for intracranial large artery occlusion with underlying atherosclerosis. J Neurointerv Surg 10(8),746–750(2018).
CHANG Y, KIM B M, BANG O Y, et al. Rescue Stenting for Failed Mechanical Thrombectomy in Acute Ischemic Stroke: A Multicenter Experience. Stroke 49(4),958–964(2018).
Li C, Wu C, Wu L, et al. Basilar Artery Occlusion Chinese Endovascular Trial: Protocol for a prospective randomized controlled study. Int J Stroke 17(6),694–697(2022).
Foley LM, Hitchens TK, Barbe B, et al. Quantitative temporal profiles of penumbra and infarction during permanent middle cerebral artery occlusion in rats. Transl Stroke Res 1(3),220–229(2010).
Touzani O, Young AR, Derlon JM, Baron JC, MacKenzie ET. Progressive impairment of brain oxidative metabolism reversed by reperfusion following middle cerebral artery occlusion in anaesthetized baboons. Brain Res 767(1),17–25(1997).
Kang R, Gamdzyk M, Tang H, Luo Y, Lenahan C, Zhang JH. Delayed Recanalization-How Late Is Not Too Late? Transl Stroke Res 12(3),382–393(2021).
Rahman AA, Amruta N, Pinteaux E, Bix GJ. Neurogenesis After Stroke: A Therapeutic Perspective. Translational stroke research 12(1),1–14(2021).
Tang H, Gamdzyk M, Huang L, et al. Delayed recanalization after MCAO ameliorates ischemic stroke by inhibiting apoptosis via HGF/c-Met/STAT3/Bcl-2 pathway in rats. Exp Neurol 330,113359(2020).
Zheng W, Matei N, Pang J, et al. Delayed recanalization at 3 days after permanent MCAO attenuates neuronal apoptosis through FGF21/FGFR1/PI3K/Caspase-3 pathway in rats. Exp Neurol 320,113007(2019).
Legrand L, Tisserand M, Turc G, et al. Fluid-Attenuated Inversion Recovery Vascular Hyperintensities-Diffusion-Weighted Imaging Mismatch Identifies Acute Stroke Patients Most Likely to Benefit From Recanalization. Stroke 47(2),424–427(2016).
Verclytte S, Fisch O, Colas L, Vanaerde O, Toledano M, Budzik JF. ASL and susceptibility-weighted imaging contribution to the management of acute ischaemic stroke. Insights Imaging 8(1),91–100(2017).
Lansberg MG, Cereda CW, Mlynash M, et al. Response to endovascular reperfusion is not time-dependent in patients with salvageable tissue. Neurology 85(8),708–714(2015).
Chimowitz MI, Lynn MJ, Derdeyn CP, et al. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med 365(11),993–1003(2011).
SSYLVIA Study Investigators. Stenting of Symptomatic Atherosclerotic Lesions in the Vertebral or Intracranial Arteries (SSYLVIA): study results. Stroke 35(6),1388–1392(2004).
Vora NA, Shook SJ, Schumacher HC, et al. A 5-item scale to predict stroke outcome after cortical middle cerebral artery territory infarction: validation from results of the Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution (DEFUSE) Study. Stroke 42(3),645–649(2011).

No competing interests reported.

Supportingdata.xlsx

Download PDF

Version 1

posted

You are reading this latest preprint version

Efficacy and Safety of Endovascular Therapy for 34 cases of Progressive Ischemic Stroke in Posterior Circulation with Large Artery Stenosis/Occlusion

Status:

Version 1

Abstract

Figures

Introduction

Methods

Results

Comparison of clinical data between the two groups

Primary and secondary outcomes were compared between the two groups at 90 days

The safety analysis of the two groups was compared

Effect of delayed recanalization

Discussion

Conclusions

Declarations

References

Additional Declarations

Supplementary Files

Status:

Version 1